you Galena SELLAS thank call. joining first for of following of end everyone, is our the Will. call you, and earnings and This today’s at us merger Thank morning, Good XXXX. on reverse the
know, develop immunotherapies mission you area for hematological our As SELLAS commercialize is of and solid a cancers. cancer at and wide to
pipeline license GPS, Memorial with lead galinpepimut-S, Sloan-Kettering a or late pembrolizumab Cancer with Keytruda, monotherapy candidate, stage combination tumor is inhibitor a collaboration in with evaluated currently agreement or in was Center which our under our includes and and Our types as PD-X checkpoint in multiple Merck. being
and in developing NPS, we for breast negative are cancer nelipepimut-S, MD Anderson announced Cancer Center. triple or NeuVax, or which which IIb Phase just We originated results also positive
QX progress made During and and GPS clinical regulatory significant will early NPS, about QX, have which talk we I and shortly. with
sheet $XX We plans approximately year, corporate our enables balance the advancements of our with for also made and million bolsters closing key pursue our our financing in this which programs. to us clinical July of
the We complaint company. dismissal have have with by a of agreements. and sheet SELLAS court agreed JGB also JGB’s just the the in litigation terminate by of all payment added $X.X from also debenture of This followed against million to them. JGB our to and our connection balance related
is clear, we have outstanding our now debt other to be Just no JGB extinguished debt. and
clinical first progress our pipeline, to with our like to we candidate, with currently discuss Turning where stand made the I’d lead we’ve GPS.
have compelling study. including been GPS, I the III myeloid a trials Phase acute Given from of Phase evidence II Phase pivotal and our planning we leukemia,
majority GPS complete designation aims stem response, unmet all achieve the AML, orphan you some this, patients we a to or cell of transplant, receive, residual about and Despite designation evidence acute myeloid chemotherapy older allergenic orphan X% FDA and CR. may harbor patients no still XX-year of hematopoietic by in drug EMA. the can provide the which and or, or treatments transplant, To essentially we need in to both patients meaningful and fast-track drug in hematopoietic serious the only years shown and AML patient area patients for AML and benefit aside leukemia, have been treat. include of disease. is which group to date, stem CR Current by AML instances, therapies, group, aim in to know, CR. is of As cell have constitutes an medical older, This from XX minimal
As opportunity to benefit real here GPS provide we for to these see a a therapeutic result, patients.
the XXXX. have early AML and enter to we registrational with the know, reached study patients As we in into trial Phase you the to first FDA III already expect in consensus enroll
sensitized The Merck development I/II, Merck’s open and type collaboration Keytruda invade by GPS is with administered trial combination anti mitigated which in upon clinical PD-X label, basket thus cells. synergy five-arm Phase against The efforts GPS premised Keytruda. by GPS pharmacodynamic and second whereby immunobiological GPS microenvironment is Keytruda, two the around of is the with agents, our destroy specifically the potential the therapy of between patient’s to pillar own WTX and cells, efficacy tumor immune cancerous our are with our of allowing
blocker types solid we XX% of which trial. the is aimed with of Bristol-Myers setting ovarian immune were XX%. Opdivo and ovarian, are but IgG as in data patients XX% are reminder, efficacy dose in XX in concentrate patients with to AML-treated Keytruda striking well patients also at clinical recurrent to robust XX ASCO PD-X in with studying treatment The immune to of or on The achieves possible macroscopic to this presented GPS and one of Merck The and more historical remission expression, receive primary approach. tumor progression-free up also GPS include or ovarian, WTX-specific at in year evaluate checkpoint Sloan-Kettering small least study Opdivo, clinical breast alone combination saw that label, inhibitor progression an I/II disease, in CDX fallopian be free and of mounting GPS June patients Squibb. to will only include in was PD-X greater a XX% a and other the observed studied of the informative in at responses, as who of cell of GPS who lung open a cancer WTX will and presence this Memorial studied single the patients was the second colorectal, arm, XX%. compared response. study survival of remained safety trial we’re CDX and rate than These cancer tube cancers which We with Keytruda triple Furthermore, indications high of response overall another basket As combination hypomethylaters. or in no on with collaboration activity combination in tumors peritoneal in and Phase combo negative nivolumab, with
the patients. final of months, annual were Society targeting of Immunotherapy between and positive NPS Medical the at cohort. in HERX we Monitoring additional NeuVax, data with have independent with final in sites meetings and significant in clinical Data now XX Phase Safety with patients to exciting patient low or for follow-up the have follow-up, statistically patients. for clinically control turn both After of we of IIb We by October begun Society the meaningful we in X.XXX. cohort a breast of to this the of and numerous our also combination combination like quarter activated refer These same XX-month from this landmark relapse p-value screen months low more of TNBC of with X+/X+ our European from lower, compared data an which nelipepimut-S the to April death favor to low-expressing we median trial trastuzumab HERX an to I’d which presented in Cancer plus cancer have and of despite plus/minus p-value of We had experience triple NeuVax even benefiting program, around trastuzumab as of in difference or of and the NPS which the of and negative an showed, the the ratio aggressive TNBC years. the of ratio system prospective, hazard breast arm, clinically They TNBC. trial protein, that XX% fall. up patients XX% rate clinical was the in cohort at all the recurrence to interim controlled X.XXX highly at period, was and randomized, trastuzumab, of that breast The IIb, independent, seven of thus TNBC a data in cancer of of a investigator-sponsored single-blinded, also patients. three make including reported of Phase or which follow-up Herceptin, trial an alone. NPS X.XX majority cancer, immune detected the attack year, significant, risk those reduction cancer a of year a the is XX.X% breast hazard or antigen patients the designed as and cancers, data the active clinically statistically recognize is prime the to longer efficiently XX.X observed breast analysis HERX this and defined Board Oncology reviewed maintained
in these Cancer analysis there from no Immunotherapy DSMB the both week, for was Last reiterated optimal FDA NeuVax meetings, highly regulatory presented the results, from potential TNBC death. preplanned benefit seek TNBC. and globally. Importantly, the on patients, Society in HLA-AXX+ clinical expeditiously a data effect safety noted meaningful positive subgroups which annual relapse consistent to is relative of Asian were most Based earlier of profile reduction on showing the significant for efficacy as differences arms. XX.X% the exciting of of particularly NPS this its of prevalent in in development secondary and risk recommendation at a to indicates a We the the it found allele data in X.XXX subgroup, be across with population p-value HLA including statistically clinically or guidance
and the path are expeditious for hope work NPS agreement development to and optimal, with closely forward with reach we most agency regulatory We the continue where to TNBC. with in the month FDA efficient next meeting and
to have to stated, we NPS very forward previously also soon. potential we are for providing discussions partnering continuing updates advance look you to further and As
early Gene to net part of to also Before two offering cash I of investors in third July, and clinical approximately earlier. for new important Mack, of our the for call events financial in allowed CFO, equity the resulted regulatory of was go The proceeds up our I us completion of the cash, influx corporate results, the mentioned This activities. but note only over quarter million, the to I’d to the influx to importance through the company. the quarter into turn SELLAS our in ramp of have not like fundamental which $XX
York New The we leaving related favor. important in dispute interests entered of our contractual and of by our our remaining litigation XXXX. Court the in debenture our we breach that This million in in from District of In a the was reached all April into the the were District our JGB they granted development predecessor thus substantive by debenture, commenced all to Last secured $X.X JGB paid and a settlement related terminated, of late other the litigation and to week, JGB for contract, JGB. with our US dismiss debt October, Southern had which whereby of us counterclaims, the announced counterclaims senior the final all have this balance very claims, of full place resolution deciding and security underlying in motion agreements removed brought Galena the while sheet.
the expenses. We are to which litigation this the our of requested I’ll includes over us reimbursement now damages have received litigation we fees counterclaims, in and legal our turn behind to and Gene. indeed to call pleased have
